We are live on
!
Find out more
BC
Broadfin Capital Portfolio holdings
AUM
$747M
1-Year Est. Return
100.56%
This Fund
S&P 500
This Quarter
Est. Return
+28.21%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$484M
AUM Growth
-$276M
(-36%)
Cap. Flow
-$350M
Cap. Flow
% of AUM
-72.29%
Top 10 Holdings %
Top 10 Hldgs %
53.23%
Holding
55
New
5
Increased
9
Reduced
24
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PETX
Aratana Therapeutics, Inc.
PETX
|
+$13.8M |
| 2 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$7.59M |
| 3 |
Myriad Genetics
MYGN
|
+$7.31M |
| 4 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$5.08M |
| 5 |
Matinas BioPharma
MTNB
|
+$2.94M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TSRO
TESARO, Inc.
TSRO
|
+$32.8M |
| 2 |
DexCom
DXCM
|
+$15.8M |
| 3 |
Iovance Biotherapeutics
IOVA
|
+$15.8M |
| 4 |
ADMA Biologics
ADMA
|
+$9.71M |
| 5 |
NSTG
NanoString Technologies, Inc.
NSTG
|
+$8.38M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 82.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Iovance Biotherapeutics
IOVA
$2.24B
| $41.2M | 8.5% |
4,328,303
-1,622,850
| -27% | -$15.8M |
|
|
NVRO
2
DELISTED
NEVRO CORP.
NVRO
| $38.9M | 8.04% |
622,615
-121,800
| -16% | -$5.73M |
|
|
CPRX
3
DELISTED
Catalyst Pharmaceutical
CPRX
| $29.9M | 6.17% |
5,856,998
-411,300
| -7% | -$1.21M |
|
|
PETX
4
DELISTED
Aratana Therapeutics, Inc.
PETX
| $26.1M | 5.4% |
7,258,135
+3,175,000
| +78% | +$13.8M |
|
|
BDSI
5
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $23.2M | 4.79% |
4,375,066
| – | – |
|
6
Travere Therapeutics
TVTX
$5.16B
| $23M | 4.75% |
1,016,114
| – | – |
|
|
GBT
7
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $20.9M | 4.32% |
395,309
+154,400
| +64% | +$7.59M |
|
|
ZGNX
8
DELISTED
Zogenix, Inc.
ZGNX
| $20.4M | 4.22% |
371,698
-164,300
| -31% | -$7.82M |
|
|
ADMS
9
DELISTED
Adamas Pharmaceuticals
ADMS
| $17.6M | 3.63% |
2,469,894
-144,574
| -6% | -$1.3M |
|
|
10
CALL
Myriad Genetics
MYGN
$559M
| $16.6M | 3.43% |
+500,000
| New | +$15.2M |
|
|
SBBP
11
DELISTED
Strongbridge Biopharma plc.
SBBP
| $13.9M | 2.87% |
2,792,049
-29,673
| -1% | -$146K |
|
|
LJPC
12
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $12.8M | 2.65% |
1,994,911
+47,370
| +2% | +$309K |
|
|
BHVN
13
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $12.7M | 2.62% |
246,900
+117,600
| +91% | +$5.08M |
|
14
Aclaris Therapeutics
ACRS
$778M
| $12.2M | 2.51% |
2,030,925
+153,423
| +8% | +$1.02M |
|
|
SCTL
15
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
| $11.2M | 2.31% |
2,129,644
-153,904
| -7% | -$1.14M |
|
|
MRTX
16
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $10.9M | 2.24% |
148,100
-51,900
| -26% | -$3.53M |
|
|
QTNT
17
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $9.9M | 2.04% |
27,466
-14,974
| -35% | -$5.27M |
|
18
CALL
Heron Therapeutics
HRTX
$90.9M
| $9.78M | 2.02% |
+400,000
| New | +$10.5M |
|
19
Incyte
INCY
$23.1B
| $8.6M | 1.78% |
100,000
-83,300
| -45% | -$6.78M |
|
|
NSTG
20
DELISTED
NanoString Technologies, Inc.
NSTG
| $8.51M | 1.76% |
355,714
-364,886
| -51% | -$8.38M |
|
|
XENT
21
DELISTED
Intersect ENT, Inc
XENT
| $8.47M | 1.75% |
263,500
-24,400
| -8% | -$755K |
|
|
SRRA
22
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $8.26M | 1.71% |
120,746
-1,262
| -1% | -$81K |
|
|
SSKN
23
DELISTED
Strata Skin Sciences
SSKN
| $8.17M | 1.69% |
286,632
+69,496
| +32% | +$2.11M |
|
|
24
DexCom
DXCM
$29.2B
| $8.04M | 1.66% |
270,000
-449,600
| -62% | -$15.8M |
|
|
ATRS
25
DELISTED
Antares Pharma, Inc.
ATRS
| $8.01M | 1.65% |
2,643,947
-800,200
| -23% | -$2.59M |
|
Similar funds
CBU
CONA
MP
SC
KGACF
BPWA
TRAM
VMI
Broadfin Capital's Q1 2019 Portfolio in Review
As of Q1 2019, Broadfin Capital held 55 positions worth $484M, down 36% from $761M the previous quarter. Its ten largest holdings account for 53% of the portfolio.
Broadfin Capital withdrew a net $350M in Q1 2019, closing 12 positions and reducing 24 holdings. Its most notable exit was TESARO, Inc., an estimated $32.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 56% a quarter earlier.
Against the trend, Broadfin Capital opened a new position in Myriad Genetics worth $7.97M.
- Broadfin Capital's largest Q1 2019 buy was Myriad Genetics: 240,000 shares worth $7.97M.
- Broadfin Capital added most to Aratana Therapeutics, Inc. in Q1 2019, an estimated $13.8M increase.
- Broadfin Capital's biggest Q1 2019 reduction was DexCom, cutting an estimated $15.8M.
- Broadfin Capital fully exited TESARO, Inc. in Q1 2019, selling an estimated $32.8M.
- Broadfin Capital's ten largest holdings make up 53% of its $484M portfolio in Q1 2019.
- Broadfin Capital opened 5 new positions and closed 12 in Q1 2019.
- Broadfin Capital's portfolio value fell 36% quarter-over-quarter to $484M.
Based on Broadfin Capital's 13F filing for Q1 2019, filed 15 May 2019.